english.prescrire.org > Spotlight > 100 most recent > Prescrire's ratings of new drugs in 2023

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's ratings of new drugs in 2023

 Marketing Authorisations   In 2023, therapeutic advances were rare, and mainly benefit cancer patients. Most newly authorised products or indications offered no advantages over existing options, and a few were more dangerous than beneficial, especially for children.
Full article available for download (free)

Prescrire’s ratings of new products and indications over the past 10 years
 
 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Bravo  BRAVO
1 0 0 0 0 0 1 0 0 0
A Real Advance  A REAL ADVANCE
2 3 1 1 2
 1 2 3 0 0
Offers an advantage  OFFERS AN ADVANTAGE
5 5 5 9 11 10 6 14 11 10
Possibly helpful  POSSIBLY HELPFUL 
15 15 9 18 22 13 18 19 23 20
Nothing new  NOTHING NEW
35 43 56 45 50 61 55 51 63 73
Judgement reserved  JUDGEMENT RESERVED
10 6 5 4 5
 9 17 12 13 10
Not acceptable  NOT ACCEPTABLE 
19 15 16 15 9
 14 10 9 14 8
TOTAL 87 87 92 92 99 108 109 108 124 121
 
Therapeutic advances in 2023 compared with
the previous 10 years
Therapeutic advances 2012-2021
 

©Prescrire 1 April 2024

Source: "Prescrire's ratings of new drugs in 2023" Prescrire Int 2024; 33 (258): 100-102. Free.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter

Subscribe now

See also:

"Prescrire's ratings
for new drugs and new
indications"
(March 2023)